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Abstract
Fluorescent proteins are widely used to study molecular and cellular events, yet this traditionally 
relies on delivery of excitation light, which can trigger autofluorescence, photoxicity, and 
photobleaching, impairing their use in vivo. Accordingly, chemiluminescent light sources such as 
those generated by luciferases have emerged, as they do not require excitation light. However, 
current luciferase reporters lack the brightness needed to visualize events in deep tissues. We 
report the creation of chimeric eGFP-NanoLuc (GpNLuc) and LSSmOrange-NanoLuc (OgNLuc) 
fusion reporter proteins coined LumiFluors, which combine the benefits of eGFP or LSSmOrange 
fluorescent proteins with the bright, glow-type bioluminescent light generated by an enhanced 
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small luciferase subunit (NanoLuc) of the deep sea shrimp Oplophorus gracilirostris. The 
intramolecular bioluminescence resonance energy transfer (BRET) that occurs between NanoLuc 
and the fused fluorophore generates the brightest bioluminescent signal known to date, including 
improved intensity, sensitivity and durable spectral properties, thereby dramatically reducing 
image acquisition times and permitting highly sensitive in vivo imaging. Notably, the self-
illuminating and bi-functional nature of these LumiFluor reporters enables greatly improved 
spatio-temporal monitoring of very small numbers of tumor cells via in vivo optical imaging and 
also allows the isolation and analyses of single cells by flow cytometry. Thus, LumiFluor reporters 
are inexpensive, robust, non-invasive tools that allow for markedly improved in vivo optical 
imaging of tumorigenic processes.
Introduction
A number of in vivo imaging technologies, for example magnetic resonance imaging (MRI), 
positron emission tomography (PET), PET-MRI, PET-computed tomography (PET-CT) and 
ultrasound have been developed and used in the clinic (1,2). The prohibitive costs and 
laborious nature of MRI and PET has limited their use for pre-clinical investigations of 
developmental and pathological processes, and for monitoring the response of disease to 
therapeutic agents. To address this issue, a variety of bioluminescent imaging (BLI) and 
fluorescence imaging reporter systems have been developed for preclinical studies, yet these 
reporters lack the in vivo penetration (sensitivity) or duration and strength (intensity) of 
signal that are needed to provide quantitative, real-time and inexpensive in vivo imaging (3–
5). For example, the routinely used ATP-dependent firefly and click beetle luciferases, as 
well as the ATP-independent Renilla and Gaussia luciferases, are limited by light absorption 
and by their reported physical instability to conditions manifest in vivo, including changes in 
temperature, pH and urea concentration (6). As a consequence, the utility of these 
luciferases reportedly benefit from imaging with long acquisition times, often in excess of 5 
minutes, and use within nude (nu/nu) or shaved mice since less fur or lighter fur allows more 
signal to reach the detector. Collectively, these features limit their utility, particularly in 
more high-throughput, pre-clinical drug screening efforts (7–9).
Some multi-modal imaging reporters have been developed that permit the analysis or 
isolation of single cells by methods such as flow cytometry and fluorescence-activated cell 
sorting (FACS), respectively. However, the signal intensities of these reporters have limited 
sensitivity in vivo, and the cassettes encoding these reporters are large, thus restricting their 
application when using viral delivery methods that require space to encode transgenes or 
shRNAs (10–14). Accordingly, a compact multi-modal reporter having enhanced signal 
intensity is needed for preclinical cancer studies. To meet this need, a variety of reporters 
and knock-in mouse models have been developed that allow one to monitor, albeit at low 
resolution, the development and progression of neoplastic disease, and its response to 
therapeutics (2,9,15–18).
The ideal in vivo reporter should combine the benefits of high fluorescent signal intensity 
with the low background associated with bioluminescent molecules, which would permit 
single cell analysis as well as spatial and temporal monitoring in live animals. However, the 
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utility of fluorescent molecules is hindered in vivo by the requirement for externally 
provided excitation light that generates auto-fluorescence and has limited penetration due to 
absorption by tissues. Conversely, bioluminescent enzymes are limited by wide variations in 
signal intensity and duration. To resolve these problems, bioluminescence resonance energy 
transfer-based (BRET) reporters employing direct fusion of a donor luciferase moiety and a 
fluorescent acceptor moiety have emerged as promising tools for monitoring complex 
biological processes, including tumor development and progression (19,20). The majority of 
BRET reporters are designed with Renilla luciferase (RLuc) and variants thereof, which 
serve as the donor molecule to a yellow fluorescent acceptor molecule, although firefly 
luciferase (FLuc) BRET fusions have also been made. While several BRET reporter fusions 
have been described, these reporters suffer from sub-optimal acceptor activation, due to the 
poor overall levels and kinetics of light production generated by most luciferases, which is 
in part due to auto-inactivation by enzymatic by-products (4,21–28). To overcome these 
challenges, we utilized the enhanced small luciferase subunit (NanoLuc) of the deep-sea 
shrimp Oplophorus gracilirostris, which displays extremely bright, stable, glow-type 
luminescent properties and physical stability, with >150-fold brighter luminescence 
compared to firefly and renilla luciferases and >2 hours signal half-life (6,29).
Here we report the creation and markedly improved imaging properties of novel BRET 
reporters we coin LumiFluors, which are fusions of enhanced Green Fluorescent Protein 
(eGFP, QY=0.6) or long stokes shift mOrange (LSSmOrange, QY=0.45; a red-shifted GFP 
variant, (30)) to NanoLuc (GpNLuc and OgNLuc, respectively). Specifically, we document 
that these LumiFluors are highly sensitive optical reporters for monitoring tumorigenesis, 
and mechanistically show that the much brighter in vivo signals of these BRET reporters is 
due to intramolecular energy transfer from the intense luminescent signal of NanoLuc to the 
fused fluorophore. This creates an optical reporter that is activated without the need for UV 
excitation, has little auto-fluorescence, and that can be used to FACS sort cells that stably or 
inducibly express these reporters. Further, the small size of LumiFluor reporter cassettes 
allows their incorporation into several viral vector delivery systems. Finally, assessments of 
the GpNLuc and OgNLuc LumiFluor reporters in both solid and soft tumor models 
demonstrated exquisitely sensitive monitoring of tumor development at both shallow and 
deep tissue levels and facile analyses of tumor cells ex vivo by flow cytometry. Thus, 
LumiFluor reporters are broadly applicable and highly sensitive optical reporter tools that 
can be used for real-time, non-invasive in vivo spatio-temporal monitoring of molecular and 
cellular events.
Materials and Methods
Cell lines and luciferase assays
HEK293T cells (ATCC; CRL-11268) were maintained in DMEM medium (Invitrogen) 
supplemented with 10% FBS (Premium Select; Atlanta Biologicals), GlutaMAX 
(Invitrogen), and PSG (penicillin, streptomycin, and L-glutamine, Invitrogen). Human Raji 
Burkitt lymphoma cells (ATCC; CCL-86) were transduced with concentrated RIEP 
retroviral particles (plasmid was kindly provided by C. Miething, Uniklinikum Freiburg, 
Freiburg in Breisgau, Germany) in the presence of Ecotropic Receptor Booster (Clontech). 
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Cells were then selected with puromycin (1μg/ml) and maintained in RPMI 1640 media 
supplemented with 10% FBS and PSG. All cell lines procured from ATCC were 
characterized by Short Tandem Repeat (STR) profiling. NSCLC A549-pBABE and A549-
LKB1 cells were previously characterized and kindly provided by Dr. Frederic J. Kaye (31) 
and maintained in RPMI 1640 media supplemented with 10% FBS and PSG antibiotics. 
Mouse lymphoma cell lines were generated by crossing the Eu-Myc transgenic mouse with 
the Rosa(26)rtTA transgenic mouse (JAX#006965). At the age of 8 weeks, offspring 
carrying Eu-Myc and Rosa(26)rtTA alleles were closely monitored for tumor development. 
Lymphomas were then harvested and homogenized in PBS with 10% FBS and the 
erythrocytes were lysed. The cells were then filtered through a 40 μm nylon filter and plated 
in 45% IMDM (with 25 mM HEPES) (GIBCO), 45% DMEM (high glucose, GIBCO), 10% 
FBS with 1% penicillin/streptomycin, 4 mM L-glutamine, 25 μM β-mercaptoethanol, 1× 
sodium pyruvate and 10 ng/ml mouse IL7 (R&D Systems). The cells were passaged several 
times to create a stably growing cell line. All cells were cultured in standard, humidified 
conditions (37°C, 5% CO2).
Transfection of HEK293T cells for luciferase assays was carried out using Lipofectamine 
2000 (Life Technologies). Luminescence was measured 24 hr post-transfection on an 
Envision plate reader (Perkin Elmer) following addition of Nano-Glo Luciferase Assay 
Substrate (Promega).
Construction and expression of the GpNLuc and OgNLuc LumiFluor reporters
The enhanced Green Fluorescent Protein (eGFP) or long stokes shift mOrange 
(LSSmOrange) cDNAs lacking a stop codon were PCR amplified and cloned with 5′ BspMI 
and 3′ EcoRV restriction enzyme sites into the pRetroX-Tight-Puro vector (Clontech) in 
place of the PuromycinR cassette. Orientation of the eGFP and LSSmOrange inserts and the 
lack of a stop codon were confirmed by sequencing. In-frame fusion of an DISGG peptide 
linker and NanoLuc to eGFP or LSSmOrange was achieved by a restriction enzyme-free, 
two step PCR cloning protocol. Briefly, two separate sets of PCR primers were designed 
with overlapping regions of homology to the new pRetroX-eGFP or pRetroX-LSSmOrange 
vectors and NanoLuc. These were then used to amplify each respective region, and then 
transformed into competent E. coli. Recombination of the DISGG peptide linker-NanoLuc 
fragment into the pRetroX-eGFP and pRetroX-LSSmOrange vectors was confirmed by 
sequencing.
In vitro of characterization of recombinant luciferases
For in vitro characterization of recombinant luciferases, luminescence intensity was 
measured in white opaque 384-well microplates (OptiPlate-384 HS, PerkinElmer Inc.) using 
2104 EnVision Multilabel Plate Reader (PerkinElmer Inc.). The assay reagent contained 50 
mM Tris-HCl, pH 8.0, 150 mM NaCl and 50 μM Nano-Glo substrate (furimazine, FZ; 
Promega Corporation) or 100 μM coelenterazine; CLZ (Biosynth International, Inc.). 
Luminescence intensity was recorded 3.0 min after adding the assay reagent to the 
respective luciferase dilutions (5×10−2 – 1.56×10−3 μM). Emission spectral scans of all 
recombinant luciferases (50 nM each) were performed in white opaque 96-well microplates 
(OptiPlate-96, PerkinElmer Inc.) using SpectraMax M5 fluorescence microplate reader 
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(Molecular Devices, LLC). Emission spectra were recorded from 390 nm to 600 nm using 
the integration time of 1000 ms with 5-nm step increments. The assay reagent for the 
emission spectral scans contained 50 mM Tris-HCl, pH 8.0, 150 mM NaCl and 50 μM FZ) 
(Promega Corporation) or 100 μM CLZ (Biosynth International, Inc.).
Subcutaneous tumor xenografts
A549-pBABE-GpNLuc and A549-LKB1-GpNLuc cells were cultured, dissociated via 
trypsin digestion and suspended in a 1:1 mixture of PBS and Matrigel (BD Biosciences). 
Cell suspensions of either A549-pBABE or A549-LKB1 (200μL) containing 5×102, 5×103, 
1×105 or 5×105 cells were subcutaneously implanted as shown (Fig. 3) in 4–6 week old 
NOD/SCID mice. In vivo luminescence of transplanted cells was measured on days 1 and 2 
post implantation and once every seven days using an in vivo imager (IVIS Spectrum; 
Xenogen).
Xenograft tumor volume measurements
To determine tumor volume by external caliper, the greatest longitudinal diameter (length) 
and the greatest transverse diameter (width) were determined. Tumor volume based on 
caliper measurements were calculated using the modified ellipsoidal formula, Tumor volume 
= 1/2(length × width2), as described (32).
Orthotopic NSCLC xenografts
A549-pBABE-GpNLuc and A549-LKB1-GpNLuc cells were dissociated via trypsin 
digestion, suspended in PBS and 5×105 cells were injected into the tail-vein of NOD/SCID 
mice. The luminescence signal from implanted tumors cells were measured once every 
seven days using an in vivo imager (IVIS Spectrum; Xenogen).
Orthotopic Eμ-Myc lymphoma allografts or Burkitt lymphoma xenografts
Eμ-Myc or Burkitt lymphoma cells stably expressing GpNLuc were resuspended in PBS and 
1×106 sorted GFP+ cells were injected via tail vein into syngeneic Albino C57Bl/6 or NOD/
SCID recipients, respectively. The luminescence signal from implanted tumors cells were 
measured once every seven days unless otherwise specified using an in vivo imager (IVIS 
Spectrum or Bruker Xtreme Optical and X-ray small animal imaging system). Tissues 
infiltrated with tumor cells that were identified by bioluminescence imaging (BLI) were 
collected for flow cytometry analysis.
Bioluminescence imaging
In vitro BLI was performed using an IVIS Spectrum one min after addition of Nano-Glo 
Luciferase Assay Substrate (furimazine; 2-furanylmethyl-deoxy-coelenterazine) following 
the manufacturer’s specifications (Promega). In vivo bioluminescent imaging was performed 
on isoflurane-anesthetized animals 5 min after injection of the indicated doses of furimazine 
either i.p. or i.v. tail-vein. Images were captured with open filter and acquisition times of 60 
seconds or less at the indicated settings. Data were analyzed using Living Image software.
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Development and analyses of bifunctional LumiFluor BRET reporters
Brighter reporter proteins that exhibit durable signal emission are needed for spatial and 
temporal imaging of molecular and cellular processes in vivo. The advent of intramolecular 
BRET fusion reporters has made significant strides in this effort, where the ability to auto-
illuminate fused fluorescent probes generates higher quantum yields than that offered by 
luciferase molecules alone (33). However, previous attempts at creating chimeric 
fluorescent-bioluminescent fusions have primarily employed the flash-type light-emitting 
properties of Renilla luciferase (RLuc), and variants thereof, but these fail to generate the 
intense, stable and durable signals required for truly sensitive in vivo imaging applications 
(Table 1).
Brightness of luciferase proteins is a function of quantum yield, catalytic rate and sensitivity 
to product inhibition (33). Thus, we reasoned that one could engineer a more robust, auto-
regulatory BRET fusion reporter using the enhanced luciferase variant of Oluc-19 
(NanoLuc; NLuc), previously generated by directed evolution. Notably, NanoLuc produces 
three orders of magnitude more luminescence than RLuc when provided with an optimized 
substrate (furimazine), due to combined improvements in all three parameters governing 
brightness (6). We predicted that the intense and stable glow-type light emitted by NanoLuc, 
which ranges from 440–480 nm, could be successfully employed for BRET to excite 
fluorescent proteins having a high quantum yield such eGFP in cis, by substrate-dependent 
chemical energy transfer (Fig. 1A). The crystal structure of eGFP (34) and molecular 
modeling of the structure of NanoLuc were used to guide the design of the chimeric reporter 
(Fig. 1B). Using this model, a short flexible (5-residue) amino acid linker between the N-
terminal eGFP and C-terminal NanoLuc (GpNLuc LumiFluor) moieties was optimized to 
allow independent folding of the two proteins and to maintain the close physical proximity 
(range of 30 – 70 Å) required for efficient intramolecular energy transfer (Fig. 1B and Table 
1).
To rigorously evaluate the optical properties of the optimized GpNLuc BRET reporter 
fusion, we compared GpNLuc directly to another recently described BRET fusion reporter 
based on enhanced RLuc (RLuc8.6) and a YFP variant (Venus), Nano-lantern-YNL, whose 
spatial arrangement was optimized by circular permutations of Venus rather than molecular 
modeling (Table 1) (22). As expected given their optimized donor/acceptor configurations, 
analysis of purified GpNLuc compared to Nano-lantern protein revealed similar BRET ratio 
and efficiency profiles. However, the GpNLuc BRET ratio was 3–4.5-fold greater compared 
to that reported for BRET3 and BRET6 fusion reporters (Fig. 1C and Table 1). Further, 
while Nano-lantern exhibits improved brightness over other reported BRET fusions (22), the 
GpNLuc LumiFluor displays 70-fold higher peak emission intensity, with 85-fold more 
luminescence than Nano-lantern when provided furimazine, or 8-fold higher peak emission 
intensity, with 45-fold more luminescence than Nano-lantern when provided with each 
luciferases preferred substrate, despite similar energy transfer characteristics (Fig. 1C and 
Supplementary Fig. S1A).
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Given its compact size, the GpNLuc fusion was cloned into a retrovirus (pRetroX-Tight-
MCS-GpNLuc) and used to generate cell lines stably expressing the reporter 
(Supplementary Fig. S1B). To verify the spectral characteristics and proper expression of 
the GpNLuc fusion protein (46-kDa), HEK293T cells were transiently transfected with 
increasing concentrations of this retroviral construct constitutively expressing GpNLuc or 
with equivalent concentrations of eGFP alone or NanoLuc alone (Fig. 1D and 
Supplementary Fig. S1C). GpNLuc has a 10-fold increase in total light output over NanoLuc 
alone, which was slightly higher but similar to that observed by analysis of purified protein, 
and, not surprisingly, several orders of magnitude more intense than eGFP in the absence of 
excitation light. Importantly, fluorescence microscopy confirmed functional eGFP activity 
of GpNLuc, and luciferase assays confirmed concentration-dependent luciferase activity of 
this chimeric reporter (Supplementary Fig. S1C). Finally, western blot analysis confirmed 
the presence of the predicted 46-kDa GpNLuc fusion protein (Fig. 1D). Thus, both the eGFP 
and NanoLuc moieties of the GpNLuc chimera are functional and their fusion creates a 
markedly improved BRET reporter that can be used to transduce, image and FACS sort 
target cells to allow, for example, the evaluation of tumor cell growth in vitro and in vivo 
(Fig. 1E).
Fluorescent-bioluminescent properties of GpNLuc in reporter tumor cells ex vivo
To characterize the in vitro properties of GpNLuc reporter, mouse Eμ-Myc lymphoma and 
human A549 non-small cell lung cancer (NSCLC) tumor cell lines were transduced with 
retroviruses expressing GpNLuc and stable clones selected by FACS sorting GFP+ cells. 
These GpNLuc-expressing tumor cells were then serially diluted and the total light emitted 
was imaged using a cooled CCD camera following treatment with furimazine 
(Supplementary Fig. 2A, B, top). Quantifying bioluminescence as a function of cell number 
revealed that the minimum number of detectable cells was about 8–16 cells/well for both 
cell lines, which is 40–60 fold better than the numbers of NSCLC cells that are required for 
detection using conventional firefly luciferase (35).
The imaging data were also evaluated using a photo multiplier tube-based (PMT) plate 
reader equipped with an enhanced luminometer capable of ultra-sensitive luminescence 
measures less than 5 amol/well. The minimum number of detectable cells by fluorescence 
was approximately 31,000 lymphoma and 125,000 NSCLC cells/well. Strikingly, however, 
this number was as low as 4–8 cells/well for both cell lines when assessing luminescence 
intensity (Supplementary Fig. 2A, B, bottom). The highly sensitive detection of GpNLuc 
versus eGFP fluorescence alone corresponds to >3 orders of magnitude more light signal 
and to detecting 8,000–30,000 fold fewer cells, respectively. Finally, stable GpNLuc 
expression and single cell analysis of serially passaged cells showed that GpNLuc-
expressing lymphoma and NSCLC cell lines were ≥95% GFP positive after two weeks of 
culture, validating their use for non-invasive in vivo imaging (Supplementary Fig. 2C, D).
GpNLuc signal intensity and sensitivity in vivo
Blue-shifted light emissions are scattered by tissues and are absorbed by hemoglobin in vivo. 
Thus, the narrow, blue-shifted emission range of NanoLuc is not optimal for penetrating 
mammalian tissues and sensitive in vivo optical imaging (36). To initially assess the utility 
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of the enhanced spectral profile and intense signal properties of the GpNLuc LumiFluor in 
vivo, subcutaneous xenografts were performed with varying numbers of (LKB1-null) A549-
GpNLuc NSCLC cells (A549-GpNLuc), and these were compared to A549-GpNLuc cells 
that were also engineered to express the tumor suppressor LKB1 (A549-LKB1-GpNLuc) 
(Fig. 2A). Previous reports have claimed the ability to detect fewer than 10 cells in vivo 
using conventional luciferases (7,8). However, in these studies images were captured with 
an open filter and acquisition times of 5 minutes or more, and in some cases several days 
post-transplant. To test the in vivo sensitivity of the GpNLuc LumiFluor reporter, images 
were captured as indicated with an open filter and acquisition times of 60 seconds or less. 
Longitudinal monitoring with bioluminescent imaging (BLI) revealed that ≤500 GpNLuc-
expressing cells are easily detected using brief image acquisition times on the first day post 
transplant and that GpNLuc effectively tracks the inhibitory affects of LKB1 on NSCLC 
tumor growth (Fig. 2A and Supplementary Fig. S3A–C). Quantitation of signal-to-noise 
ratios for 500 cells revealed that the GpNLuc signal is 2–3 orders of magnitude above 
background signal generated in control mice similarly injected with substrate; thus, far fewer 
cells can be successfully imaged. To define the optimal dose of furimazine substrate and the 
stability of the resulting GpNLuc signal, subcutaneous xenografts were established with 
500,000 GpNLuc-expressing tumor cells, and tumors were allowed to develop to 1500-mm3. 
Recipient mice were then administered with specific doses of furimazine and followed by 
periodic BLI (Fig. 2B). Analysis of signal intensity and stability revealed that 250 μg/kg and 
500 μg/kg furimazine produced 12–16 fold higher signal than a 50 μg/kg dose, although all 
three doses displayed a remarkably stable signal output, with a t½ of 40 minutes (Fig. 2B). 
These remarkable in vivo properties for the GpNLuc LumiFluor are in stark contrast with the 
apparent rapid in vivo signal decay rate of secreted NanoLuc, which has a t½ of 5–10 
minutes (36).
The sensitivity of the GpNLuc reporter was also assessed by a direct comparison of BLI and 
external caliper measurements in subcutaneous xenografts (Fig. 2C). Temporal analysis 
identified a significant difference between the A549-GpNLuc and A549-LKB1-GpNLuc 
NSCLC cohorts as early as day 11 post-transplant using BLI, which was not evident until 
day 21 using caliper measurements. We next tested the ability of the GpNLuc signal to 
penetrate through deep tissue using an orthotopic lung tumor model. As few as 500,000 
GpNLuc-expressing A549 NSCLC cells were injected via tail-vein into recipient mice, 
allowed to colonize the lungs, and recipients were followed by longitudinal BLI monitoring 
(Fig. 2D). Three-dimensional (3D) reconstruction performed using the Living Image DLIT 
algorithm confirmed that GpNLuc signal was easily detected from deep within the lungs and 
ex vivo BLI of these surgically resected lungs validated the DLIT reconstruction (Fig. 2D, 
Supplementary Fig. S4A–C and Supplementary Video S1). Notably, the intensity of the 
GpNLuc signal allowed the detection of micro-metastases at regional lymph nodes 
(Supplementary Fig. S4D).
GpNLuc monitoring of soft tumors by BLI and flow cytometry
In vivo monitoring of models of hematological malignancies is challenging, as experimental 
parameters often rely on end-point analysis such as overall survival, or periodic blood 
sampling, WBC cell counts and flow cytometry analyses. To test the utility of GpNLuc 
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LumiFluor reporter in detecting such malignancies, we established orthotopic allografts 
following i.v. (tail vein) transplantation of two independently derived Eμ-Myc B cell 
lymphomas expressing the GpNLuc reporter (Fig. 3 and Supplementary Fig. S5). 
Longitudinal monitoring revealed a progressive increase in signal intensity, which increased 
by more than two orders of magnitude on day 14 post-transplant versus that manifest on 
days 1 and 2 (Fig. 3A and Supplementary Fig. S6, S8A). Temporal analysis confirmed that 
monitoring tumor development in deep tissues with this LumiFluor reporter is technically 
feasible given the detection of lymphoma cells in the lungs of recipient mice 
(Supplementary Fig. S5C, D). Homing and colonization of lymphoma cells into the spleen, 
inguinal lymph nodes and spinal bone marrow was easily and strongly detected as early as 2 
days post-transplant, followed shortly thereafter by detection within the axial, cervical and 
lumbar/sacral lymph nodes (Fig. 3B and Supplementary Fig. S5E, S6). This represents a 
significantly reduced time frame for detection compared to the two weeks required for most 
leukemia models using conventional luciferase reporters having inferior light emission (15). 
Differences in observed signal intensity and half-life could be attributed to the route of 
substrate administration. While an i.p. administration route was used for monitoring the 
NSCLC tumor models (Fig. 2), substrate was administered via an i.v. route for the Eμ-Myc B 
cell lymphoma orthotopic allografts or human Burkitt lymphoma xenografts, and analysis of 
signal intensity and stability revealed that a 250 μg/kg dose administered i.v. also displays 
stable signal output (Supplementary Fig. 7A). Both DLIT 3D-reconstruction with the IVIS 
Spectrum and optical imaging coupled with X-ray performed with a Bruker In Vivo Xtreme 
optical/X-ray imager confirmed the anatomic origins of observed signals (Fig. 3B, 
Supplementary Fig. S6B, S7B and Supplementary Video S2). Finally, ex vivo BLI of 
surgically resected tissues or flow cytometry analyses of surgically resected tissues on day 
14 following lymphoma transplant validated these findings (Fig. 3C and Supplementary Fig. 
S5D, E, and Fig. S8).
Enhanced output of LumiFluor reporters requires intramolecular energy transfer
To test if increased light output and broader optical profile generated via the intramolecular 
BRET within GpNLuc truly enabled more sensitive in vivo imaging, Y67A and Y67C 
GpNLuc substitution mutants within the chromophore of the eGFP (37) moiety were 
generated (Fig. 4A). As a control, mutation of the adjacent threonine residue not predicted to 
disrupt the eGFP chromophore (T66G) was also generated in GpNLuc. Finally, a second 
LumiFluor reporter was generated that has an even broader optical profile, by fusing long 
stokes shift mOrange (LSSmOrange, a red-shifted GFP variant) to NanoLuc (OgNLuc). 
HEK293T cells were transfected with equal concentrations of retroviral constructs 
constitutively expressing NanoLuc, the GpNLuc or OgNLuc LumiFluors, or the GpNLuc 
point mutants (Fig. 4A). As predicted, like GpNLuc, there were 10-fold increases in total 
light output of OgNLuc or GpNLuc-T66G over that of NanoLuc alone, and there was a 
marked attenuation in light output by the GpNLuc-Y67A and GpNLuc-Y67C mutants. 
Further, FACS analyses of retrovirus transduced Eμ-Myc B cell lymphomas confirmed that 
OgNLuc displays a red-shifted fluorescent signal and that the GpNLuc-Y67C mutant cannot 
generate a GFP signal (Fig. 4B and Supplementary Fig. S9).
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To compare their in vivo activity, BLI analyses of orthotopic Eμ-Myc lymphomas allografts 
expressing these reporters were performed. These analyses confirmed that the BLI potential 
of the GpNLuc-Y67C mutant was comparable to NanoLuc alone, with much inferior in vivo 
optical properties requiring 4–6 fold longer exposure times (25 and 40 seconds, respectively) 
versus the GpNLuc LumiFluor (6 seconds) (Fig. 4C). Notably, despite having an apparent 
equivalent total light output in vitro and half the exposure time in vivo (3 seconds), OgNLuc 
displayed an even greater (2–4 fold) increase for in vivo signal output relative to GpNLuc, 
likely owing to its red-shifted emission that is capable of enhanced tissue penetration. Based 
on these image acquisitions, signal-to-noise ratios were quantified and revealed that 
GpNLuc and OgNLuc have a signal working range between 3–4 orders of magnitude above 
background signal generated in control mice similarly injected with substrate. Thus, 
compared to conventional in vivo fluorescent or bioluminescent imaging, the GpNLuc and 
OgNLuc LumiFluor BRET reporters generate a robust, high-intensity signal that is perfectly 
suited for sensitive, non-invasive in vivo optical imaging (Fig. 4D).
Discussion
The development of luciferase molecules having enhanced light-emitting properties such as 
NanoLuc is as active arena of study (4,5,38–41). However, due to absorption and scattering 
of the blue-shifted, short wavelength light emitted by NanoLuc, this reporter cannot 
penetrate tissues and the signal generated by NanoLuc has a short half-life in vivo (6,36). 
Here we describe the generation and characterization of a novel class of in vivo BRET 
imaging reporters coined LumiFluors that overcome these deficiencies. Specifically, 
LumiFluors have the desired fluorescent-bioluminescent spectral and optical properties that 
allow sensitive imaging both ex vivo and in vivo, and they also allow one to isolate and fully 
characterize target cells using flow cytometry. Indeed, the enhanced strength, stability and 
duration of signal, and the deep tissue penetration capabilities of the GpNLuc and OgNLuc 
LumiFluors dramatically reduce image acquisition times making them more desirable than 
conventional reporters for in vivo imaging. The increased sensitivity and imaging speed 
offered by LumiFluors provides improved monitoring of tumor development and the 
detection of small metastatic lesions (42).
The development and characterization of the GpNLuc and OgNLuc BRET reporters was 
achieved by a molecular modeling-guided approach that resulted in a short, flexible peptide 
linker that enables highly efficient donor energy transfer to the paired acceptor to generate 
intense bioluminescent signals. Oplophorus gracilirostris luciferase (OLuc) naturally has 
high quantum yields (QY) (29), but even brighter signals were achieved by pairing the 
enhanced version of OLuc (NanoLuc) to high QY fluorophores (eGFP QY=0.6 and 
LSSmOrange QY=0.45). Compared to NanoLuc alone, LumiFluor BRET reporters are more 
than 10-fold brighter and thus display increased tissue penetration thereby overcoming 
current limitations associated with reporters used for in vivo imaging. A key advantage of 
LumiFluor reporters is that they provide the user with the ability to non-invasively monitor 
specific cell populations in vivo and to then isolate these cells by FACS. This is, for 
example, particularly useful for characterization of sub-populations and heterogeneity in 
primary and metastatic tumors, and in circulating tumor cells, in orthotopic or even 
genetically engineered mouse models (GEMM). Moreover, their strength of signal suggests 
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that LumiFluors may allow one to locate, isolate and characterize rare cancer stem/initiating 
cells and dormant/resistant tumor cells.
A potential limitation to the use of LumiFluor reporters is their dependence on the substrate 
furimazine. While furimazine was previously shown to be stable in media in the presence of 
serum (6), it is a coelenterazine analog and coelenterazine is known to be a substrate for 
multidrug resistance (MDR1) P-glycoprotein (PGP), which can lead to its rapid export from 
cells that express MDR1, thereby impacting signal intensities (43). Future experiments will 
evaluate the transport properties of furmazine by MDR1 as well as its ability to cross the 
blood-brain barrier.
Many uses of LumiFluors are feasible, for example as reporters in GEMM, as fusions with 
proteins to monitor real-time biological processes in cells, and as biosensor tags for 
antibodies or small molecule probes that home to select target cells, which could be used to 
visualize responses in vivo and to determine the margins of select tissues and/or tumors, to 
aid in surgical procedures (17,44,45). Finally, LumiFluors can also be used in traditional 
BRET assays to study protein:protein or ligand:protein interactions by developing a split 
LumiFluor reporter for complementation assays (46,47).
The fluorescent component of LumiFluor reporters also permits multiplexing. For example, 
the distinct spectral characteristics of GpNLuc and OgNLuc allow one to simultaneously 
monitor signals coupled to multiple molecular and cellular events in either in vitro or in vivo 
formats. Importantly, the sustained intense signals produced by these two LumiFluors also 
increases the confidence for monitoring rare coincident events in preclinical models, for 
example the interplay of immune cells with tumors, tumor-stromal interactions and how 
these, and the fate of primary tumors and micrometastases, are affected by treatment with 
therapeutics. Finally, engineering the NanoLuc moiety of LumiFluors, so that it emits light 
at different wavelengths, should allow for the intramolecular activation of a broad spectrum 
of fluorescent proteins that will expand the repertoire and imaging capabilities of these novel 
reporters.
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Development and validation of an eGFP-NanoLuc (GpNLuc) bifunctional LumiFluor 
reporter. A, schematic of the GpNLuc reporter. The N-terminus of GpNLuc is derived from 
eGFP, which is followed by a flexible 5-residue linker (DISGG), and the C-terminus is 
derived from NanoLuc. Following hydrolysis of its substrate furimazine, the light emitted by 
the NanoLuc moiety activates the eGFP moiety via bioluminescence resonance energy 
transfer (BRET) in cis. B, structural model and functional evaluation of the GpNLuc 
LumiFluor. A model of GpNLuc was generated by combining the structure of eGFP 
(pdb4EUL) with a model of NanoLuc based on sequence homology to fatty acid binding 
protein (pdb1B56). The in-frame 5-residue DISGG linker was added between the C-
terminus of eGFP and the N-terminus of NanoLuc. The distance between the NanoLuc 
active site and the eGFP fluorophore ranges between 30 to 70 Å based on this model, with a 
mean of 52 Å. C, normalized spectral emission scans of native proteins. Equimolar amounts 
of expressed and purified recombinant NanoLuc, Renilla, GpNLuc, and Nano-lantern BRET 
fusion proteins were aliquoted and emission intensities measured in triplicate in the presence 
of either furimazine (FZ; 50 μM) or coelenterazine (CLZ, 100 μM). D, expression and 
functional comparison of the GpNLuc fusion reporter to eGFP and NanoLuc alone. Left, 
HEK293T cells were transfected with equal concentrations of each respective retroviral 
construct and luciferase assays were performed 24 hr post-transfection (n = 4; mean ± 
s.e.m.). Right, western blot analyses of whole cell lysates from HEK293T cells transfected 
with NanoLuc (lane 1), eGFP (lane 2), or GpNLuc (lane 3). E, approach used to validate the 
functional utility of the bifunctional GpNLuc reporter for in vivo bioluminescent imaging 
and ex vivo flow cytometry analyses.
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GpNLuc signal strength and stability in A549 NSCLC xenograft and orthotopic transplants. 
A, A549-GpNLuc cells or A549 cells engineered to also express the LKB1 tumor suppressor 
(A549-LKB1-GpNLuc) were injected subcutaneously into the front and rear flanks of 
recipient NOD/SCID mice with the indicated numbers of tumor cells to gauge limits of 
signal detection (minimum number of detectable cells) 1 day following injection. 
Furimazine was injected intraperitoneally (i.p.) and bioluminescence images were captured 
for the two cohorts, which were monitored longitudinally from day 1 to day 28 post-
transplantation (lens aperture = f/1; image exposure time = 60 seconds on Day 1 or 7 
seconds on Day 28; binning = 8; field of view = 13.3 cm; and emission set to open filter). B, 
in vivo dose-response kinetics of GpNLuc signal strength. Mouse subcutaneous xenografts 
were established with A549-GpNLuc cells (5 × 105) and signal strength was monitored 
temporally in response to i.p. furimazine administration at the indicated doses when tumor 
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volume reached 1500 mm3 (n = 3). C, direct comparison of subcutaneous tumor growth 
monitored temporally by bioluminescent imaging (BLI; top) and caliper measurements 
(bottom) for mouse xenografts (5 × 105 cells) from A549-GpNLuc or A549-LKB1-GpNLuc 
cohorts (n = 3). A significant difference was detectable between the A549-GpNLuc and 
A549-LKB1-GpNLuc cohorts on day 11 by BLI but not until day 21 by caliper 
measurements (*P < 0.05; **P < 0.01; ***P < 0.001). D, tissue penetrating ability of 
GpNLuc signal was evaluated by orthotopic transplantation of A549-GpNLuc cells (1 × 106) 
injected intravenously (via tail vein) into NOD/SCID mice. Furimazine was injected 
intravenously (i.v.) and 2D (left) and 3D (right) bioluminescence images were captured. 
Images are representative of mice monitored longitudinally from day 1 to day 49 post-
transplantation (lens aperture = f/1; image exposure time = 60 seconds; binning = 8; field of 
view = 6.6 cm; and emission set to open filter).
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Longitudinal bioluminescence imaging quantification and flow cytometry analyses of 
GpNLuc-expressing Eμ-Myc lymphoma transplants. A, allografts of Eμ-Myc mouse 
lymphoma cells stably expressing GpNLuc (1 × 106) that were injected i.v. into syngeneic 
Albino C57Bl/6 recipient mice (n = 10). Left, furimazine was injected intravenously (i.v.) 
and ventral and dorsal bioluminescence images were captured from day 1 to day 14 post-
transplantation (lens aperture = f/1; image exposure time = 6 seconds; binning = 8; field of 
view = 22.6 cm; and emission set to open filter). Right, quantification of bioluminescent 
signal intensities in vivo from indicated lymph nodes and tissues colonized by B cell 
lymphoma. B, direct comparison of tumor burden on day 2 versus 14 post-transplantation by 
2D (left) or 3D (right) bioluminescence imaging. Representative images are shown. C, ex 
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vivo confirmation of tumor burden by flow cytometry analyses of surgically resected lymph 
nodes and tissues identified by BLI. Graphs are representative of mice analyzed on day 14 
post-transplantation (n = 3).
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Intramolecular BRET in LumiFluors drives fluorophore excitation/emission and is essential 
for sensitive in vivo imaging. A, comparison of catalytically inactive GpNLuc-Y67A and 
GpNLuc-Y67C mutants, as well as the red-shifted LSSmOrange-NLuc (OgNLuc) fusion, to 
either GpNLuc or NanoLuc alone. HEK293T cells were transfected with equal 
concentrations of each respective retroviral construct and luciferase assays were performed 
24 hr post-transfection (n = 3; mean ± s.e.m.). B, flow cytometric analysis of Eμ-Myc mouse 
lymphoma cells, along with serially passaged Eμ-Myc lymphoma cells engineered to express 
NanoLuc, GpNLuc, GpNLuc-Y67A, GpNLuc-Y67C, GpNLuc-T66G or OgNLuc, 
confirmed effects of mutagenesis on the fluorescence excitation capacity of NanoLuc on 
eGFP and on LSSmOrange. C, allografts of Eμ-Myc mouse lymphoma cells expressing 
either NanoLuc, GpNLuc, GpNLuc-Y67C, or OgNLuc (1 × 106) were injected i.v. into 
syngeneic Albino C57Bl/6 recipient mice (n = 3). Furimazine was injected i.v. and ventral 
bioluminescence images (BLI) were captured on day 7 post-transplantation (lens aperture = 
f/1; image exposure time: NanoLuc = 25 seconds, GpNLuc = 6 seconds, GpNLucY67C = 40 
seconds, or OgNLuc = 3 seconds; binning = 8; field of view = 22.6 cm; and emission set to 
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open filter). D, model comparing and contrasting conventional in vivo fluorescent imaging 
to new methods offered by GpNLuc and OgNLuc LumiFluor reporters. Ectopic excitation of 
fluorescent reporters in vivo results in significant autofluorescence whereas local excitation 
of fluorophores by intramolecular energy transfer from a fused NanoLuc partner prevents 
global autofluorescence and augments overall signal output and detection.
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